Chapman Tripp is the law firm of choice for UK-based private equity firm Hg in its deal with Orion Health.
Hg has agreed to take a majority stake in Orion’s core business Rhapsody, as well as invest in Orion’s Population Health business. The deal, subject to conditions including Overseas Investment Office green light, is worth $205m.
Bell Gully earlier confirmed it is acting for Orion.
The deal comes as Chapman Tripp is having a strong year in M&A, with it being the leading New Zealand firm in numerous league tables.
Chapman Tripp is the only New Zealand firm in Mergermarket’s “Global & Regional M&A Report H1 2018,” Thomson Reuters’ “M&A Review – Legal Advisors First Half 2018,” and Bloomberg’s “Global M&A Market Review – Legal Rankings 1H 2018.”
Partner Tim Tubman, who leads the firm’s national corporate group, sees a strong M&A pipeline.
“The solid M&A deal volumes of last year have continued, but unlike last year, we are seeing a resurgence in mega-deals, such as Cigna Corporation’s purchase of ANZ Bank New Zealand’s business OnePath Life NZ for $700m, in which we advised ANZ, and the sale of Shell New Zealand to Vienna-based oil and gas company OMV for $794m,” he said.
Top Firm guides banking giant on key $700m sale
Leading firm makes senior appointments